British regulators approved a GlaxoSmithKline drug to treat those at high risk of developing severe Covid-19 symptoms which appears effective against the new Omicron variant.
Preclinical data showed that the drug retains activity against key mutations of the new Omicron SARS-CoV-2 variant. It is a monoclonal antibody, a type of protein that attaches to the spike protein of the coronavirus, reducing its ability to enter the body's cells.
A single dose of the drug was found to reduce the risk of hospitalisation and death by 79 percent in high-risk adults with symptomatic COVID-19 infection.
Testing is ongoing "to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021."
See What’s Next in Tech With the Fast Forward Newsletter
Tweets From @varindiamag
Nothing to see here - yet
When they Tweet, their Tweets will show up here.
